CDK1 and prostate carcinoma: Furthermore, liraglutide has been shown to enhance the chemosensitivity of pancreatic cancer cells to gemcitabine [18] and prostate cancer cells to enzalutamide [19], and to increase radiosensitivity in prostate cancer cells through AMPK activation and subsequent inhibition of p-mTOR, cyclin B, and p34cdc2 activation [24].